Model-based approach for a new Prolonged-Release (PR) formulation of ivabradine: PK and PKPD assessment to support bioequivalence

MIDD

Cardiovascular

Trial design and analysis

Regulatory interactions

Pharmacometrics

PAGE 33 (2025) Abstr 11678

Skerlep M, Mezzalana E, Chenel M, Gendrot N, Fouliard S